Outcomes in liver transplant recipients with hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade
Authors:
Open Access
- 20 October 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 10 (11) , 1372-1378
Abstract
Hepatitis B virus (HBV) recurrence following liver transplantation (LTx) has been controllable primarily with the use of hepatitis B immune globulin (HBIg) and lamivudine (LAM). However, HBV resistance to LAM and/or HBIg has become an increasing problem prompting the use of newer antiviral agents. The purpose of our study was to investigate the association between therapy, HBV breakthrough, and allograft / patient survival in HBV-positive liver transplant recipients. We performed a retrospective review of the medical records of patients that were transplanted for HBV from June 1994 to May 2003. A total of 92 patients, positive for either hepatitis B surface antigen (HBsAg) or HBV deoxyribonucleic acid (DNA) pretransplant, received LAM monotherapy or HBIg (6 months) plus LAM therapy post-liver transplant. HBV breakthrough post-LTx was noted in 14 patients. All patients had detectable HBV DNA prior to liver transplantation; none of the patients that were HBV DNA negative prior to transplant had detectable HBV DNA posttransplant. Of these 14, 9 patients (64%) were switched from LAM to adefovir dipivoxil (ADF) and 5 patients (36%) to tenofovir disoproxil fumarate (TNV). In conclusion, pre-LTx HBV viremia should be considered in planning post-LTx prophylaxis. Trials to evaluate oral antiviral agents in combination with or without HBIg therapy are needed. (Liver Transpl 2004;10:1372-1378.)Keywords
This publication has 24 references indexed in Scilit:
- Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudineTransplantation, 2003
- Prophylaxis and treatment of recurrent hepatitis B after liver transplantationTransplantation, 2003
- Hepatitis B: Progress in the last 15 yearsLiver Transplantation, 2002
- Liver transplantation: the Italian experienceDigestive and Liver Disease, 2002
- Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?Journal of Viral Hepatitis, 2002
- A concise update on the status of liver transplantation for hepatitis B virus: The challenges in 2002Liver Transplantation, 2002
- Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulinHepatology, 1998
- EFFICACY OF LAMIVUDINE IN CONTROLLING HEPATITIS B VIRUS RECURRENCE AFTER LIVER TRANSPLANTATIONTransplantation, 1998
- Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosisThe Lancet, 1996
- IMPROVED OUTCOME OF ORTHOTOPIC LIVER TRANSPLANTATION FOR CHRONIC HEPATITIS B CIRRHOSIS WITH AGGRESSIVE PASSIVE IMMUNIZATIONTransplantation, 1996